Abstract A127: Targeting replication stress in pancreatic cancer: results of a phase 1b trial of azenosertib and gemcitabine in second line pancreatic cancer after progression on FOLFIRINOX
Treatment options for patients with pancreatic ductal adenocarcinoma (PDAC) who have had progressive disease on FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and infusional 5-fluorouracil) are limited, and patients are typically treated with gemcitabine and nab-paclitaxel. Targeting therapeutic vulnerabilities...